Effects of Exogenous Hormones and Reproductive Factors on Female Melanoma: A Meta-Analysis

References

• Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo (Brooklyn). 2014;28(6):1005–1011.
   PubMed Web of Science ®Google Scholar
• Fattouh K, Ducroux E, Decullier E, et al. Increasing incidence of melanoma after solid organ transplantation: a retrospective epidemiological study. Transpl Int. 2017;30(11):1172–1180. doi:10.1111/tri.1301128700114
   PubMed Web of Science ®Google Scholar
• Rizvi SMH, Aagnes B, Holdaas H, et al. Long-term change in the risk of skin cancer after organ transplantation: a population-based nationwide cohort study. JAMA Dermatol. 2017;153(12):1270–1277. doi:10.1001/jamadermatol.2017.298429049612
   PubMed Web of Science ®Google Scholar
• Carr S, Smith C, Wernberg J. Epidemiology and risk factors of melanoma. Surg Clin North Am. 2020;100(1):1–12. doi:10.1016/j.suc.2019.09.00531753105
   PubMed Web of Science ®Google Scholar
• Ascha M, Ascha MS, Tanenbaum J, Bordeaux JS. Risk factors for melanoma in renal transplant recipients. JAMA Dermatol. 2017;153(11):1130–1136. doi:10.1001/jamadermatol.2017.229128746700
   PubMed Web of Science ®Google Scholar
• Robsahm TE, Bergva G, Hestvik UE, Moller B. Sex differences in rising trends of cutaneous malignant melanoma in Norway, 19542008. Melanoma Res. 2013;23(1):70–78. doi:10.1097/CMR.0b013e32835c7e4823222548
   PubMed Web of Science ®Google Scholar
• Reed KB, Brewer JD, Lohse CM, Bringe KE, Pruitt CN, Gibson LE. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2012;87(4):328–334. doi:10.1016/j.mayocp.2012.01.01022469345
   PubMed Web of Science ®Google Scholar
• Enninga EAL, Moser JC, Weaver AL, et al. Survival of cutaneous melanoma based on sex, age, and stage in the United States, 19922011. Cancer Med. 2017;6(10):2203–2212. doi:10.1002/cam4.115228879661
   PubMed Web of Science ®Google Scholar
• Van Rooij N, Adams A, De’Ambrosis B, Nathan V, Hayward N, Whiteman D. Cluster of pregnancy-associated melanoma: a case report and brief update. J Dermatol. 2020;47:1054–1057. doi:10.1111/1346-8138.1545532557800
   PubMed Web of Science ®Google Scholar
• Anaya-Prado R, Ruvalcaba-Soto EN, Anaya-Fernandez MM, et al. Melanoma and pregnancy. A case report. J Obstet Gynaecol. 2017;37(7):950–951. doi:10.1080/01443615.2017.130832028468571
   PubMedGoogle Scholar
• Wielowieyska-Szybinska DK, Spalkowska M, Wojas-Pelc A. Melanoma in pregnancy: a case report and review of the literature. Postepy Dermatol Alergol. 2015;32(6):483–487. doi:10.5114/pdia.2014.4400626755917
   PubMed Web of Science ®Google Scholar
• Zampetti A, Feliciani C, Landi F, Capaldo ML, Rotoli M, Amerio PL. Management and dermoscopy of fast-growing nevi in pregnancy: case report and literature review. J Cutan Med Surg. 2006;10(5):249–252. doi:10.2310/7750.2006.0004717234109
   PubMed Web of Science ®Google Scholar
• Feskanich D, Hunter DJ, Willett WC, et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer. 1999;81(5):918–923. doi:10.1038/sj.bjc.669078710555769
   PubMed Web of Science ®Google Scholar
• Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol. 2009;20(2):358–364. doi:10.1093/annonc/mdn58918725391
   PubMed Web of Science ®Google Scholar
• Hicks BM, Kristensen KB, Pedersen SA, Holmich LR, Pottegard A. Hormone replacement therapy and the risk of melanoma in post-menopausal women. Hum Reprod. 2019;34(12):2418–2429. doi:10.1093/humrep/dez22231803923
   PubMed Web of Science ®Google Scholar
• Osterlind A, Tucker MA, Stone BJ, Jensen OM. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer. 1988;42(6):821–824. doi:10.1002/ijc.29104206033192324
   PubMed Web of Science ®Google Scholar
• Beral V, Ramcharan S, Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer. 1977;36(6):804–809. doi:10.1038/bjc.1977.265597478
   PubMed Web of Science ®Google Scholar
• Adam SA, Sheaves JK, Wright NH, Mosser G, Harris RW, Vessey MP. A case-control study of the possible association between oral contraceptives and malignant melanoma. Br J Cancer. 1981;44(1):45–50. doi:10.1038/bjc.1981.1457259960
   PubMed Web of Science ®Google Scholar
• Bain C, Hennekens CH, Speizer FE, Rosner B, Willett W, Belanger C. Oral contraceptive use and malignant melanoma. J Natl Cancer Inst. 1982;68(4):537–539.6951070
   PubMedGoogle Scholar
• Beral V, Evans S, Shaw H, Milton G. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer. 1984;50(5):681–685. doi:10.1038/bjc.1984.2366498066
   PubMed Web of Science ®Google Scholar
• Holman CD, Armstrong BK, Heenan PJ. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer. 1984;50(5):673–680. doi:10.1038/bjc.1984.2356498065
   PubMed Web of Science ®Google Scholar
• Helmrich SP, Rosenberg L, Kaufman DW, et al. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. J Natl Cancer Inst. 1984;72(3):617–620.6583445
   PubMedGoogle Scholar
• Zanetti R, Franceschi S, Rosso S, Bidoli E, Colonna S. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int J Epidemiol. 1990;19(3):522–526. doi:10.1093/ije/19.3.5222262243
   PubMed Web of Science ®Google Scholar
• Le MG, Cabanes PA, Desvignes V, Chanteau MF, Mlika N, Avril MF. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control. 1992;3(3):199–205. doi:10.1007/BF001242521610966
   PubMed Web of Science ®Google Scholar
• Palmer JR, Rosenberg L, Strom BL, et al. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control. 1992;3(6):547–554. doi:10.1007/BF000527521420858
   PubMed Web of Science ®Google Scholar
• Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am J Epidemiol. 1995;141(10):943–950. doi:10.1093/oxfordjournals.aje.a1173617741124
   PubMed Web of Science ®Google Scholar
• Smith MA, Fine JA, Barnhill RL, Berwick M. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol. 1998;27(5):751–757. doi:10.1093/ije/27.5.7519839729
   PubMed Web of Science ®Google Scholar
• Westerdahl J, Olsson H, Masback A, Ingvar C, Jonsson N. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br J Cancer. 1996;73(9):1126–1131. doi:10.1038/bjc.1996.2168624275
   PubMed Web of Science ®Google Scholar
• Freedman DM, Sigurdson A, Doody MM, Rao RS, Linet MS. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes Control. 2003;14(9):847–857. doi:10.1023/B:CACO.0000003839.56954.7314682442
   PubMed Web of Science ®Google Scholar
• Naldi L, Altieri A, Imberti GL, et al. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. Ann Epidemiol. 2005;15(7):545–550. doi:10.1016/j.annepidem.2004.10.00516029848
   PubMed Web of Science ®Google Scholar
• Lea CS, Holly EA, Hartge P, et al. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol. 2007;165(5):505–513. doi:10.1093/aje/kwk04017158470
   PubMed Web of Science ®Google Scholar
• Holly EA, Weiss NS, Liff JM. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst. 1983;70(5):827–831.6573527
   PubMedGoogle Scholar
• Adami HO, Persson I, Hoover R, Schairer C, Bergkvist L. Risk of cancer in women receiving hormone replacement therapy. Int J Cancer. 1989;44(5):833–839. doi:10.1002/ijc.29104405152583865
   PubMed Web of Science ®Google Scholar
• Holly EA, Cress RD, Ahn DK. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev. 1994;3(8):661–668.7881339
   PubMed Web of Science ®Google Scholar
• Cervenka I, Mahamat-Saleh Y, Savoye I, et al. Oral contraceptive use and cutaneous melanoma risk: a French prospective cohort study. Int J Cancer. 2018;143(10):2390–2399. doi:10.1002/ijc.3164429978471
   PubMed Web of Science ®Google Scholar
• Donley GM, Liu WT, Pfeiffer RM, et al. Reproductive factors, exogenous hormone use and incidence of melanoma among women in the United States. Br J Cancer. 2019;120(7):754–760. doi:10.1038/s41416-019-0411-z30814688
   PubMed Web of Science ®Google Scholar
• Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, et al. Postmenopausal hormone use and cutaneous melanoma risk: a French prospective cohort study. Int J Cancer. 2019;145(7):1754–1767. doi:10.1002/ijc.3215030671928
   PubMed Web of Science ®Google Scholar
• Cervenka I, Al Rahmoun M, Mahamat-Saleh Y, et al. Exogenous hormone use and cutaneous melanoma risk in women: the European prospective investigation into cancer and nutrition. Int J Cancer. 2020;146(12):3267–3280. doi:10.1002/ijc.3267431506954
   PubMed Web of Science ®Google Scholar
• Zaridze D, Mukeria A, Duffy S. Risk factors for skin melanoma in Moscow. Int J Cancer. 1992;52(1):159–161. doi:10.1002/ijc.29105201281500220
   PubMed Web of Science ®Google Scholar
• De Giorgi V, Gori A, Savarese I, et al. Role of BMI and hormone therapy in melanoma risk: a case-control study. J Cancer Res Clin Oncol. 2017;143(7):1191–1197. doi:10.1007/s00432-017-2387-528289899
   PubMed Web of Science ®Google Scholar
• Lambe M, Thorn M, Sparen P, Bergstrom R, Adami HO. Malignant melanoma: reduced risk associated with early childbearing and multiparity. Melanoma Res. 1996;6(2):147–153. doi:10.1097/00008390-199604000-000108791273
   PubMed Web of Science ®Google Scholar
• Neale RE, Darlington S, Murphy MF, Silcocks PB, Purdie DM, Talback M. The effects of twins, parity and age at first birth on cancer risk in Swedish women. Twin Res Hum Genet. 2005;8(2):156–162. doi:10.1375/twin.8.2.15615901479
   PubMed Web of Science ®Google Scholar
• Stoer NC, Botteri E, Ghiasvand R, et al. Reproductive factors and risk of melanoma: a population-based cohort study. Br J Dermatol. 2019;181(2):282–289. doi:10.1111/bjd.1777130748007
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700. doi:10.1136/bmj.b270019622552
   PubMed Web of Science ®Google Scholar
• GA SB W, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa: Ottawa Health Research Institute University of Ottawa; 2000.
   Google Scholar
• Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? BMJ. 1998;316(7136):989–991. doi:10.1136/bmj.316.7136.9899550961
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188. doi:10.1016/0197-2456(86)90046-23802833
   PubMedGoogle Scholar
• Higgins JPGS. Cochrane handbook for systematic reviews of interventions version 5.1.0. Cochrane Collaboration. 2011.
   Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. doi:10.2307/25334467786990
   PubMed Web of Science ®Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.6299310563
   PubMed Web of Science ®Google Scholar
• Young P, Purdie D, Jackman L, Molloy D, Green A. A study of infertility treatment and melanoma. Melanoma Res. 2001;11(5):535–541. doi:10.1097/00008390-200110000-0001511595893
   PubMed Web of Science ®Google Scholar
• Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 19682004. Br J Cancer. 2006;95(3):385–389. doi:10.1038/sj.bjc.660326016819539
   PubMed Web of Science ®Google Scholar
• Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner’s oral contraception study. BMJ. 2007;335(7621):651. doi:10.1136/bmj.39289.649410.5517855280
   PubMed Web of Science ®Google Scholar
• Hannibal CG, Jensen A, Sharif H, Kjaer SK. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study. Cancer Causes Control. 2008;19(7):759–765. doi:10.1007/s10552-008-9138-518340541
   PubMed Web of Science ®Google Scholar
• Kvaskoff M, Bijon A, Mesrine S, Boutron-Ruault MC, Clavel-Chapelon F. Cutaneous melanoma and endogenous hormonal factors: a large French prospective study. Am J Epidemiol. 2011;173(10):1192–1202. doi:10.1093/aje/kwq50321415032
   PubMed Web of Science ®Google Scholar
• Botteri E, Stoer NC, Sakshaug S, et al. Menopausal hormone therapy and risk of melanoma: do estrogens and progestins have a different role? Int J Cancer. 2017;141(9):1763–1770. doi:10.1002/ijc.3087828685818
   PubMed Web of Science ®Google Scholar
• Mueller K, Verzi AE, Bhatt K, et al. Melanoma and chronic exposure to contraceptives containing microdoses of ethinylestradiol in young women: a retrospective study from the Research on Adverse Drug Events and Reports (RADAR) project comprising a large Midwestern U.S. patient population. J Eur Acad Dermatol Venereol. 2018;32(3):e87e88. doi:10.1111/jdv.1453428833586
   PubMed Web of Science ®Google Scholar
• Pfahlberg A, Hassan K, Wille L, Lausen B, Gefeller O. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev. 1997;25(34):309–315.9553446
   PubMedGoogle Scholar
• Karagas MR, Stukel TA, Dykes J, et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer. 2002;86(7):1085–1092. doi:10.1038/sj.bjc.660019611953854
   PubMed Web of Science ®Google Scholar
• Gefeller O, Hassan K, Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol. 1998;138(1):122–124. doi:10.1046/j.1365-2133.1998.02037.x9536234
   PubMed Web of Science ®Google Scholar
• Gandini S, Iodice S, Koomen E, Di Pietro A, Sera F, Caini S. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer. 2011;47(17):2607–2617. doi:10.1016/j.ejca.2011.04.02321620689
   PubMed Web of Science ®Google Scholar
• Barone I, Brusco L, Fuqua SA. Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res. 2010;16(10):2702–2708. doi:10.1158/1078-0432.CCR-09-175320427689
   PubMed Web of Science ®Google Scholar
• Caruntu C, Mirica A, Rosca AE, et al. The role of estrogens and estrogen receptors in melanoma development and progression. Acta Endocrinol. 2016;12(2):234–241. doi:10.4183/aeb.2016.234
   Google Scholar
• Ribeiro MPC, Santos AE, Custodio JBA. The activation of the G protein-coupled estrogen receptor (GPER) inhibits the proliferation of mouse melanoma K1735-M2 cells. Chem Biol Interact. 2017;277:176–184. doi:10.1016/j.cbi.2017.09.01728947257
   PubMed Web of Science ®Google Scholar
• Lens MB, Reiman T, Husain AF. Use of tamoxifen in the treatment of malignant melanoma. Cancer. 2003;98(7):1355–1361. doi:10.1002/cncr.1164414508820
   PubMed Web of Science ®Google Scholar
• Beguerie JR, Xingzhong J, Valdez RP. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis. Int J Dermatol. 2010;49(10):1194–1202. doi:10.1111/j.1365-4632.2010.04529.x20883410
   PubMed Web of Science ®Google Scholar